Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Medtronic
McKesson
Baxter

Last Updated: August 19, 2022

Investigational Drug Information for CC-220


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug CC-220?

CC-220 is an investigational drug.

There have been 22 clinical trials for CC-220. The most recent clinical trial was a Phase 2 trial, which was initiated on November 12th 2021.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.

There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-six international patents.

Recent Clinical Trials for CC-220
TitleSponsorPhase
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyNational Cancer Institute (NCI)Phase 1/Phase 2
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyMayo ClinicPhase 1/Phase 2
Study of Novel Regimens in Relapsed or Refractory Multiple MyelomaBristol-Myers SquibbPhase 1/Phase 2

See all CC-220 clinical trials

Clinical Trial Summary for CC-220

Top disease conditions for CC-220
Top clinical trial sponsors for CC-220

See all CC-220 clinical trials

US Patents for CC-220

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-220 See Plans and Pricing Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ) See Plans and Pricing
CC-220 See Plans and Pricing Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione Celgene Corporation (Summit, NJ) See Plans and Pricing
CC-220 See Plans and Pricing Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ) See Plans and Pricing
CC-220 See Plans and Pricing Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same Celgene Corporation (Summit, NJ) See Plans and Pricing
CC-220 See Plans and Pricing 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus Celgene Corporation (Summit, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-220

Drugname Country Document Number Estimated Expiration Related US Patent
CC-220 Australia AU2015305449 2034-08-22 See Plans and Pricing
CC-220 Australia AU2021209158 2034-08-22 See Plans and Pricing
CC-220 Brazil BR112017003620 2034-08-22 See Plans and Pricing
CC-220 Canada CA2958867 2034-08-22 See Plans and Pricing
CC-220 Chile CL2017000416 2034-08-22 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Medtronic
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.